This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Prognosis

Authoring team

The mortality rate for patients with neurofibromatosis is elevated with:

  • malignant peripheral nerve sheath tumours (MPNST) (1,2)
    • MPNST is the term now used to refer to malignant schwannomas, neurogenic sarcomas, malignant neurilemomas, neurofibrosarcomas and spindle cell sarcomas
    • approximately 50% of MPNSTs are associated with NF-1 and are often due to malignant transformation of neurofibromas
    • NF1 patients show an 8–13% lifetime risk of developing MPNSTs (1)
    • MPNSTs in NF1 usually arise within a preexisting plexiform neurofibroma (PNF)
    • MPNSTs in NF-1 have a male predilection and occur approximately a decade earlier than in the general population.
  • central nervous system tumours

Fertility may be reduced, especially in males.

Up to 75% of affected individuals may have no complications.

 

Reference:

  1. Frahm S et al. Genetic and phenotypic characterization of tumor cells derived from malignant peripheral nerve sheath tumors of neurofibromatosis type 1 patients. Neurobiol of Dis 2004;16 (1): Pages 85-91.
  2. Hillier JC, Moskovic E. The soft-tissue manifestations of neurofibromatosis type 1.Clin Radiol 2005; 60 (9): 960-967

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.